Medicosnext
CanSino Biologics
CanSino Biologics’ vaccine is a one-dose adenovirus-based vaccine that can be stored at 2–8 ºC. Its trial included 40,000 volunteers.
March 2020: China’s CanSino Biologics and the Academy of Military Medical Sciences launch phase 1 trial in Wuhan after getting regulatory approval to start human trials of their vaccine against the novel coronavirus.
June 29, 2020: Vaccine approved for military use in China.
September 15, 2020: Phase 3 trial begins in a number of countries, including Saudi Arabia, Pakistan, and Russia.
Pfizer-BioNTech
Pfizer-BioNTech’s vaccine is a two-dose mRNA vaccine that has to be stored at -70 ºC. The trial comprised of 44,000 volunteers. The company aims to produce 50 million doses in 2020 and 1.3 billion in 2021. Cost per dose is $19.50.
April 29, 2020: US company Pfizer and German start-up BioNTech begins trial of their vaccine.
November 29, 2020: Trial result shows 90% efficacy (later updated to 95%).
December 2, 2020: UK grants approval for emergency use.
December 9, 2020: Canada grants approval for emergency use.
December 11, 2020: US FDA grants emergency use authorization in USA.
Gamaleya Research Institute
Gamaleya’s vaccine (Sputnik V) is a two-dose adenovirus-based vaccine that can be stored at 2−8 ºC. Its trial included 40,000 volunteers. Cost is $10 per dose.
May 2020: Russia’s Gamaleya Research Institute announces development of Sputnik V vaccine.
August 11, 2020: Sputnik V gets regulatory approval.
September 7, 2020: Gamaleya begins trial of Sputnik V.
November 24, 2020: Trial result shows 95% efficacy.
December 2, 2020: President Putin calls for mass vaccination with Sputnik V.
Sinopharm
Sinopharm’s vaccine is a two-dose adenovirus-based vaccine that can be stored at 2–8 ºC. Its trial was done on 50,000 participants. The company is conducting late stage trials of two candidate vaccines.
July 2020: Chinese company Sinopharm begins trial of its vaccine.
August 28, 2020: Vaccine gets early approval for high risk groups in China.
September 14, 2020: Emergency use approval for health workers granted in UAE.
December 9, 2020: Trial result shows vaccine to be 86% effective.
December 9, 2020: Vaccine gets full approval in UAE.
December 13, 2020: Vaccine gets full approval in Bahrain.
Sinovac Biotech
Sinovac Biotech’s vaccine (CoronaVac) is a two-dose vaccine that can be stored at 2–8 ºC. Its trial included 26,000 participants. The vaccine triggers an immune response u
sing inactivated COVID-19 virus. The company plans to produce 600 million doses a year. Cost is $30 per dose.
July 21, 2020: Chinese company Sinovac Biotech begins trial of its vaccine in Brazil, Indonesia, and Turkey.
August 25, 2020: Deal signed with Indonesia to deliver 40 million doses.
August 28, 2020: Vaccine gets early approval for high risk groups in China.
November 9, 2020: Trial paused in Brazil due to an adverse event.
November 11, 2020: Trial resumes again.
Moderna
Moderna is a two-dose mRNA vaccine that can be stored at 2-8 ºC. Its trial included 30,000 participants. The company aims to produce 20 million doses for the
US in December 2020 and 100 million for global distribution in the next quarter. Cost is from $25-$37 per dose.
July 27, 2020: US company Moderna begins trial of its vaccine.
November 16, 2020: Trial result shows 94.5% efficacy.
November 30, 2020: Company applies to FDA for emergency use authorization of its vaccine.
December 18, 2020: Vaccine granted emergency use authorization in USA.
AstraZeneca-University of Oxford
AstraZeneca-Oxford vaccine is a two-dose adenovirus-based vaccine that can be stored at 2-8 ºC. The trial comprised of 65,000 participants. The company has received orders of 3 billion doses even before late-stage trial results. Cost is $3-$4 per dose.
August 28, 2020: UK company AstraZeneca and University of Oxford begins trial of their vaccine.
September 8, 2020: Trial paused due to safety concerns.
October 23, 2020: Trial resumes again.
November 23, 2020: Aggregated analysis of trial results shows 70% efficacy.
December 7, 2020: Serum Institute of India applies for emergency use authorization for CoviShield, the name for AstraZeneca-Oxfords’s vaccine produced by them in India.
Johnson & Johnson
Johnson & Johnson vaccine is a one-dose adenovirus-based vaccine that can be stored at 2-8 ºC. The trial comprised of 70,000 volunteers. The company aims to pr
oduce one billion doses in 2021. Cost is $10 per dose.
September 7, 2020: US company Johnson & Johnson begins trial of its vaccine.
October 12, 2020: Trial paused to investigate adverse reaction in a volunteer.
October 25, 2020: Trial resumes again.
November 16, 2020: Company announces second trial with two doses.
Novavax
Novavax vaccine is a two-dose vaccine engineered from the genetic sequence of SARS-CoV-2 that can be stored at 2-8 ºC. Its trial included 45,000 participants. Cost
is $16 per dose.
September 15, 2020: US company Novavax announces agreement with Serum Institute of India to manufacture two billion doses of it vaccine candidate.
September 28, 2020: Novavax begins trial of its vaccine in UK.
References:
1. Bloomberg, December 12, 2020, https://bloom.bg/37dzWeL
2. Healthline, November 29, 2020,
3. Biospace, November 24, 2020,
